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Abnormalities in mucus properties and clearance make a major
contribution to the pathology of cystic fibrosis (CF). Our aim was
to test the hypothesis that the defects in CF mucus are a direct
result ofmutations in theCF transmembrane conductance regulator
(CFTR) protein. We evaluated a single mucin molecule MUC1F/
5ACTR that carries tandem repeat sequence fromMUC5AC, amajor
secreted airway mucin, in a MUC1 mucin vector. To establish
whether the presence of mutant or normal CFTR directly influences
the O-glycosylation and sulphation of mucins in airway epithelial
cells, we used the CFT1-LC3 (F508 CFTR mutant) and CFT1-LCFSN
(wild-type CFTR corrected) human airway epithelial cell lines.
MUC1F/5ACTR mucin was immunoprecipitated, centricon purified,
and O-glycosylation was evaluated by Matrix-assisted laser desorp-
tion ionization and electrospray tandem mass spectrometry to de-
termine the composition of different carbohydrate structures. Mass
spectrometry data showed the sameO-glycans in bothCFTRmutant
and wild-type CFTR corrected cells. Metabolic labeling assays were
performed to evaluate gross glycosylation and sulphation of the
mucins and showed no significant difference in mucin synthesized
in six independent clones of these cell lines. Our results show that
the absence of functional CFTR protein causes neither an abnormal-
ity in mucin O-glycosylation nor an increase in mucin sulphation.
Keywords: mucus; cystic fibrosis transmembrane conductance regula-
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Respiratory failure in patients with cystic fibrosis (CF) is due to
recurrent lung infection and associated inflammatory damage,
which is caused or exacerbated by failure to clear thick mucous
secretions from the CF airway. Mucins are the major constituents
of mucus and  20 human mucins have been identified (1), which
may be either membrane-tethered or secreted. Both of these types
of mucin contribute to the glycoprotein content of mucous and
have been implicated inCFpathology (2, 3). An important feature
of human airway mucins is their post-translational modification
by O-glycosylation and sulphation, primarily within serine/
threonine-rich tandem repeats (TR), which constitute up to 70–
80% of their mass, and is a major factor determining their bio-
chemical and biophysical properties.
Whether the CF mucous secretions actually demonstrate in-
creased viscosity is controversial. A number of studies report
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that there is no rheological defect inCFmucus (4–6).Others have
shown abnormal rheology (7) that correlates with the degree of
bacterial infection and CF disease severity (8) or that is only
exhibited with increasedDNA content (9) or altered salt concen-
tration (10). Mucin abnormalities have been reported in patients
with CF, and it has been suggested that these result from muta-
tions in the cystic fibrosis transmembrane conductance regulator
(CFTR) protein having a direct effect on mucin biosynthesis.
One hypothesis is that altered mucus properties may arise from
primary changes in mucin glycosylation, through defective acidi-
fication of the trans-Golgi network altering the kinetics of pH
sensitive glycoprotein-processing enzymes (2, 11, 12). Alterna-
tively, unusual mucin properties may simply be a consequence
of volume-reduced airway surface liquid (ASL) (13).
Evidence for abnormalities in CF mucins comes from several
types of studies; however, interpretation of the data in support
of each hypothesis is controversial (14, 15). First, a number of
groups have evaluated the biochemistry of mucins derived di-
rectly from patient and control secretions. CF intestinal mucins
were found to be hyperglycosylated and to contain more fucose
and sulfate than those from control subjects (16). Respiratory
and salivary mucins from patients with CF may also exhibit
elevated sulphation and aberrant sugar composition (17, 18).
Interpretation of these data are complicated by the possibility
that there were secondary modifications of the secreted mucin
in vivo as a consequence of infection, inflammation, or pharma-
cologic intervention associated with CF. Second, a number of
groups have looked at mucin modifications in relevant cell lines
or model systems derived from CF tissues. Studies using CF
nasal epithelial cells (19) or a xenograft model (20) suggested
that increased sulphation of mucus glycoproteins was a primary
defect of disease that could be rectified by expression of wild-
type CFTR (21). In contrast, other studies showed either no
differences in sulphation or glycosylation of CF mucins in cell
culture systems (22) or reported that changes could not be res-
cued by expression of wild-type CFTR (23). Data derived from
individual cell lines must, however, be interpreted with caution
because there are known differences in the activity of glycopro-
tein processing enzymes in cultured cells that are unconnected
with mutations in CFTR (24). Activities of glycosyltransferases
and sulphotransferases synthesizing mucin type O-glycans were
shown to be CFTR-independent both in cell culture and in CF-
null mice (25).
Effective therapeutic approaches toCF lung diseasewill prob-
ably be through pharmacologic intervention or by gene therapy.
In both cases it is of considerable importance to understand if
the altered properties/viscosity of CF mucins are due to defects
in their biophysical and biochemical properties that arise inside
airway epithelial cells (e.g., by changes in O-glycosylation) or
outside these cells (e.g., by changes in ASL). The recurrent
controversy relating to the cause of the abnormal properties of
CF mucins has not produced a clear answer; hence, we have
revisited the topic.
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We previously demonstrated that CFTR expression in gen-
eral does not influence the gross levels of glycosylation or sulpha-
tion of theMUC1mucin nor the types of carbohydrate structures
attached to the MUC1 protein in the colon carcinoma cell line
Caco2 (26). These studies were limited with respect to the organ
site of origin of the cell lines evaluated (colon) and the fact that
the only cell lines available for study were Caco-2 cell clones
that expressed wild-type CFTR or had spontaneously switched
off CFTRexpression.We have now evaluated theO-glycosylation
and sulphation of TR sequence fromMUC5AC, amajor secreted
mucin in the airways (27), in appropriate matched sets of airway
cells that express mutant or wild-type CFTR.
A full-length cDNA for MUC5AC has not been assembled,
in part due to the size of the complete MUC5AC mRNA and
the instability of the TR sequences (also evident at the nucleic
acid level). There are specific antibodies that react with the
MUC5AC TR (28); however, the reactivity of some of these
may bemodulated by glycosylation of the TR.Hence, to evaluate
the O-glycosylation of the MUC5AC TR in airway cells, we
previously developed a chimeric mucin in which MUC5AC TRs
were inserted into an epitope (FLAG)-tagged MUC1 mucin
backbone that lacked the native MUC1TRs (MUC1F/5ACTR)
(29). MUC1F/5ACTR and other chimeric mucins were shown
to be useful for evaluating the O-glycosylation of mucin TRs
in vitro (29). The MUC1F/5ACTR construct was transfected into
the CFT1-LC3 airway cell line, which is homozygous for the
common F508 mutation in CFTR, and a matched cell line
CFT1-LCSFN, which has been stably transfected with wild-type
CFTR (30). This experimental system has enabled evaluation
of the O-glycosylation and sulphation of a single type of mucin
TR in cells that express mutant or wild-type CFTR. Our data
show that the presence of wild-type CFTR does not influence
the O-glycosylation (including fucosylation and sialylation) or
sulphation of the MUC1F/5ACTR mucin molecule. This sug-
gests that mucin abnormalities arise outside the airway epithelial
cell, either through altered ASL and/or extracellular factors in-
fluencing mucus properties, release, and clearance.
MATERIALS AND METHODS
Cell Lines
The CFT1-LC3 and CFT1-LCFSN cell lines (30) were kindly donated
by Dr. J. Yankaskas (University of North Carolina, Chapel Hill). CFT1
are tracheal epithelial cell lines derived from a patient with CF (homo-
zygous for the 508 mutation) that have been transformed with human
papilloma virus E6/E7 genes. The CFT1-LC3 and CFT1-LCFSN cells
were transformed with retroviral vector alone or containing the CFTR
cDNA, respectively. Cells were grown in F12–7X medium (31).
Generation of a Mammalian Expression Vector Carrying the
Epitope-Tagged Chimeric MUC1F/5ACTR Construct
Generation of the MUC1/MUC5AC chimera (MUC1F/5ACTR) was
described previously (29). MUC1F/5ACTR contains 138 amino acids
of MUC5AC TR cloned into the Bgl II and Asp I sites of MUC1FTR,
a MUC1 cDNA that lacks native MUC1 TR sequences. In previous
experiments the MUC1F/5ACTR cDNA was expressed from the -actin
promoter in the vector pH-APr1-neo. However, the neomycin resis-
tance gene in this plasmid cannot be used in the CFT1-LC3 and CFT1-
LCSFN cells as they have previously been subjected to G418 selection
(30). Instead, MUC1F/5ACTR was transferred as a Bam HI fragment,
directly from pBS to the pcDNA3.1/zeo vector. DNA was purified by
the Maxi plasmid purification kit (Qiagen, Crawley, UK).
Stable Transfection of MUC1F/5ACTR
The MUC1F/5ACTR plasmid was transfected into the CFT1-LC3 and
CFT1-LCFSN cell lines with Lipofectin (Invitrogen, Paisley, UK). Sta-
ble transfectants were selected with Zeocin at 300g/ml for CFT1-LC3
or 150 g/ml for CFT1-LCSFN, and clonal cell lines were isolated and
the expression levels of MUC1F/5ACTR checked by Western blotting.
Western Blotting
Cell lysates were prepared in NET buffer (10 mM Tris pH 7.5, 150 mM
NaCl, 5 mMEDTA) containing 1% (vol/vol) protease inhibitor cocktail
(Sigma, Poole, UK) and 1% (wt/vol) Triton X-100. Protein concentra-
tions were determined using a detergent compatible DC protein assay
(Bio-Rad, Hemel Hempstead, UK). Protein samples (crude lysate, 50 g;
purified, 10–15g) were separated on SDS-PAGEgels (3% stacker, 6%
resolving), transferred to Immobilon-P transfer membrane (Millipore,
Watford, UK), and blocked in blocking buffer (5% skim milk powder
in phosphate-buffered saline [PBS]) for 1 h. M2 antibody (anti-FLAG
epitope, Sigma) was used at a dilution of 1:1,500 in PBS with 1% skim
milk powder. Blots were incubated with the primary antibodies for 1 h
at room temperature followed by three 10-min washes with PBS
containing 0.1% Tween 20 (vol/vol). The blots were incubated with
horseradish peroxidase–conjugated rabbit anti-mouse IgG secondary
antibody (DAKO, Ely, UK) in PBS with 1% skim milk powder for 1 h
followed by washing with PBS-0.1% Tween 20 (vol/vol) as described
above. Blots were visualized using ECL reagents (Amersham, Little
Chalfont, UK) applied according to the manufacturer’s instructions and
exposed to ECL-sensitive film.
Evaluation of CFTR Expression
CFTR expression in MUC1F/5ACTR-transfected CFT1-LC3 and
CFT1-LCFSN clones was evaluated by semiquantitative RT-PCR, using
primers E1R and E1L, and quantitative RT-PCR (Taqman) as de-
scribed previously (32, 33). The semiquantitative RT-PCR method was
modified by using ramped annealing temperatures: annealing for 2 min
at 54 C for 5 cycles, at 56 C for 5 cycles, at 58 C for 10 cycles, and
finally at 60 C for 16 cycles. All other parameters of the RT-PCR
reaction were as published (33).
Immunoprecipitation
MUC1F/5ACTR glycoconjugates were purified with M2-antibody against
the FLAG epitope; 20 l of M2-conjugated agarose beads (Sigma) were
incubated with 300 g of cell lysate at 4 C for 24 h with vigorous shaking.
The agarose beads were washed twice in NET buffer (50 mM Tris,
150 mM NaCl, 1 mM EDTA, pH 7.4), and protein was eluted from
the beads by incubation with 50l of FLAG peptide (500 g/ml; Sigma)
for 24 h at 4 C with vigorous shaking.
Mass Spectrometry
Preparation of oligosaccharides. O-linked oligosaccharides were liberated
from the immunoprecipitated mucins by reductive elimination (400 l
of 1 M NaBH4 in 0.05 M NaOH at 45 C for 16 h) and desalted through
a Dowex 50W-X8(H) column. Removal of traces of detergent was
achieved by passing the desalted eluate through a Sep-Pak C18 column
(Waters, Elstree, Herts, UK). Excess borates were removed by coeva-
poration with 10% (vol/vol) acetic acid in methanol under a stream of
nitrogen.
Matrix-assisted laser desorption ionization “time-of-flight” analysis.
Chemical derivatization was performed as described previously (29).
Matrix-assisted laser desorption ionization “time-of-flight” (MALDI-
TOF) data were acquired by using a Voyager-DE STRmass spectrometer
(PerSeptive Biosystems, Framingham, MA) in the reflectron mode with
delayed extraction. Permethylated samples were dissolved in 10 l
of 80% (vol/vol) methanol in water, and 1 l of dissolved sample was
premixed with 1 l of matrix/2,5-dihydroxybenzoic acid before loading
onto a metal plate.
Collisionally activated dissociation electrospray tandem mass spec-
trometry. Collisionally activated dissociation electrospray tandem mass
spectrometry (CAD ES-MS/MS) spectra were acquired using a Q-TOF
(Micromass, Manchester, UK) instrument. The permethylated glycans
were dissolved in methanol before loading into a spray capillary coated
with a thin layer of gold/palladium, inner diameter 2 l (Proxeon,
Odense, Denmark). A potential of 1.5 kV was applied to a nanoflow
tip to produce a flow rate of 10–30 nl/min. The drying gas used was N2
and the collision gas was argon, with the collision gas pressure main-
tained at 104 millibar. Collision energies varied depending on the size
of the carbohydrate, typically between 30 and 90 eV.
Leir, Parry, Palmai-Pallag, et al.: CFTR Expression and Mucin O-Glycosylation 455
Metabolic Labeling Assays
All metabolic labeling experiments were performed in triplicate. Rela-
tive levels of glycosylation per unit protein were determined. Cell lines
were grown to  40% confluence in T75 flasks and washed three times
in PBS, and then 10 ml of F12 medium containing 7X supplement was
placed in each flask with 0.015 MBq/ml [U-14C] protein hydrolysate
(CFB25; Amersham), and 0.051 MBq/ml d-[6-3H] glucosamine hydro-
chloride (TRK398; Amersham). The cells were grown to confluence
over 4 d, cell lysates were prepared and MUC1F/5ACTR mucin immu-
noprecipitated with the M2 antibody as described above. The immuno-
precipitated material was separated on SDS-PAGE gels and visualized
by autoradiography after treatment with the fluorographic agent Amplify
(Amersham) and gel areas containing the MUC1F/5ACTR glycoprotein
were excised. The amount of 14C amino acids and 3H glucosamine present
in these gel slices was determined by scintillation counting. Counts
were then expressed as ratios comparing the level of glycosylation (3H
glucosamine) to the level of protein (14C amino acids).
The relative level of sulphation was compared with the level of glyco-
sylation. Cell cultures at 40% confluence were prepared as for glycosyla-
tion assays. F12 medium containing 7X serum-free supplement was used
with 0.296 MBq/ml [35S] Na2SO4 (SJ162; Amersham) and 0.051 MBq/ml
d-[6-3H] glucosamine hydrochloride, and the cells grown to confluence
over 4 d. Lysates were prepared as described for unlabeled cells, and
theMUC1F/5ACTR glycoprotein was purified by immunoprecipitation
with the M2 antibody. The immunoprecipitated material was separated
on SDS-PAGE gels and visualized by autoradiography as described for
the 14C amino acids/3H glucosamine experiments. The gel areas containing
the MUC1F/5ACTR glycoprotein were excised. The amounts of 35S
sulfate and 3H glucosamine were determined by scintillation counting
the excised gel slices. These counts were expressed as ratios comparing
the level of glycosylation (3H glucosamine) to the level of sulphation
(35S sulfate).
The levels of sulphation of the mucin proteins were also determined
by using F12 medium containing 7X serum-free supplement with 0.296
MBq/ml [35S] Na2SO4 and 0.093 MBq/ml [3H] amino acids (37MBq/ml;
MP Biomedicals, Irvine, CA). The cells were grown to confluence over
4 d and samples were prepared as described as above. The amounts of
35S sulfate and 3H amino acids in excised gel slices were determined.
These counts were expressed as ratios comparing the level of 35S sulfate
to 3H amino acids.
RESULTS
Expression of MUC1F/5ACTR in CFT1-LC3 and CFT1-LCSFN
Airway Epithelial Cells
Stably transfected clones of CFT1-LC3 and CFT1-LCSFN car-
rying MUC1F/5ACTR (Figure 1) were screened for chimeric
Figure 2. Expression of the MUC1F/5ACTR mucin and CFTR in CFT1-
LC3 and CFT1-LCFSN airway cells. (A ) Western blot analysis of MUC1F/
5ACTR chimeric mucins immunoprecipitated from whole cell lysates
(CFT1-LC3 clones L15, L23, and L28 and CFT1-LCFSN clones C03, C13,
and C16) and separated by 3%/6% SDS-PAGE. Detection was by M2
anti-FLAG antibody followed by rabbit anti-mouse IgG conjugated to
HRP. Migration of Full Range Rainbow protein molecular weight markers
is indicated (kD). Mucins immunoprecipitated with an excess of M2
beads from 300 g of total cell lysate were loaded in each lane. (B )
Semiquantitative RT-PCR for CFTR mRNA. The 768-bp CFTR-specific
product is marked by an arrow. For each RT-PCR reaction 2 g of total
RNA was used. Lane M, 1-kb ladder; lane 1, LCFSN; lane 2, clone C03;
lane 3, clone C13; lane 4, clone C16; lane 5, clone L15; lane 6, clone
L23; lane 7, clone L28; lane 8, no reverse-transcriptase control.
Figure 1. Diagram of epitope-tagged MUC1F/5ACTR mucin. MUC1F/
5ACTR was generated from MUC1F as described previously (29). The
position of the FLAG (M2) epitope is marked above. Dark gray rectangles
indicate TR sequence. Signal sequence, membrane spanning and cyto-
plasmic tail domains are also indicated. MUC1F (TR) and the chimeric
mucin MUC1F/5ACTR (which contains MUC5AC TR) are illustrated be-
low MUC1F. The figure is drawn to scale.
mucin expression by Western blotting of SDS/PAGE gels (Figure
2A). To exclude changes in mucin processing resulting from
clonal variation, we evaluated mucin from three clones of each
cell line carrying the same chimeric mucin. The three clones
of CFT1-LC3 carrying MUC1F/5ACTR included one with low
levels of MUC1F/5ACTR expression (L15) and two with high-
level expression (L23 and L28) (Figure 2). Similarly, one clone
of CFT1-LCFSN expressing low levels ofMUC1F/5ACTR (C03)
and two with high-level expression (C13 and C16) were chosen
for further evaluation (Figure 2A). As observed previously for
the expression of FLAG-tagged chimeric mucins in other cell
types (29, 34) multiple forms of MUC1F/5ACTR mucin were
detected in CFT1-LC3 and CFT1-LCFSN cell clones. The major
form of the MUC1F/5ACTR mucin migrated between 130 and
150 kD in these cells, a rather smaller observed mass than seen
previously in Caco2 colon carcinoma cells. However, this differ-
ence in migration might reflect different glycosylation of the
MUC1F/5ACTR mucin in the airway cells. No significant differ-
ences were detected in the migration of MUC1F/5ACTR forms
expressed in the CFT1-LC3 and CFT1-LCFSN cells.
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To confirm that the MUC1F/5ACTR mucin-expressing
clones derived from the CFT-LC3 and CFTR-LCFSN cell lines
accurately reflected the CFTR mRNA expression status of the
parental lines, semiquanititative and quantitative RT-PCR were
performed. Figure 2B shows by semiquantitative RT-PCR that, as
expected, theC03,C13, andC16 lines showedabundant transgene-
derived CFTR mRNA expression, whereas the L15, 23, and
28 lines showed much lower, though detectable, expression of
endogenous CFTR. Quantitative RT-PCR data confirmed the
differential expression levels (data not shown). This is consistent
with the expression levels of CFTR in the original description
of the parental cell lines (30).
Evaluation of the MUC1F/5ACTR O-Glycans Expressed
in CFT1-LC3 and CFT1-LCFSN Cell Clones
by Mass Spectrometry
O-glycans were prepared fromMUC1F/5ACTRmucin immuno-
precipitated from clones CFT1-LC3 L15 and L28 and CFT1-
LCFSN C03 and C13. After reductive elimination, O-glycans
were purified using Dowex and Sep-Pak C18 columns, prepared
as permethylated derivatives and analyzed by MALDI-TOF
mass spectrometry (Figure 3). Both CFTR-mutant (CFT1-LC3)
and -corrected (CFTR1-LCSFN) cell lines showed 12 peaks that
correlated to known O-glycan structures (Figures 3A and 3B; Ta-
ble 1). The compositions uniquely attributable to core 1 structures
Figure 3. MALDI-TOF MS spectra of the MUC1F/5ACTR O-glycans.
Mucin O-glycans were released by reductive elimination, purified
by Dowex and Sep-Pak C18 columns, permethylated, and ana-
lyzed as mixtures by MALDI-TOF MS. The spectra correspond to
O-glycans of MUC1F/5AC from CFT1-LC3 L28 (A ) and CFT1-
LCFSN C13 (B ). The magnification is indicated above each panel.
Note that magnification reductions have been used where com-
mon contaminating matrix-derived peaks occur in the low mass
region of the spectrum (-).
(35) include Hex1HexNAc1-ol (m/z 534), Fuc1Hex1HexNAc1-ol
(m/z 708), NeuAc1Hex1HexNAc1-ol (m/z 895), and NeuAc2Hex1
HexNAc1-ol (m/z 1,256). Additional peaks were observed at m/z
983 (Hex2HexNAc2-ol), m/z 1,157 (Fuc1Hex2HexNAc2-ol), m/z
1,344 (NeuAc1Hex2HexNAc2-ol), m/z 1,432 (Hex3HexNAc3-ol),
m/z 1,518 (NeuAc1Fuc1Hex2HexNAc2-ol), m/z 1,606 (Fuc1Hex3
HexNAc3-ol), m/z 1,705 (NeuAc2Hex2HexNAc2-ol), andm/z 1,793
(NeuAc1Hex3HexNAc3-ol). The majority of these glycans were
shown to be core 2 (35) by CAD ES-MS/MS. For both clones,
CFT1-LC3 L28 and CFT1-LCFSN C13 m/z 895 and m/z 983
were abundant peaks. Though minor differences were seen in
the relative abundance of some of the peaks between the two
spectra shown in Figure 3 (and between these and the spectra
for clones CFT1-LC3 L15 and CFT1-LCFSN C03, (not shown)),
these are likely to reflect individual clonal variation or sample
abundance differences rather than a consistent difference be-
tween the CFTR and CFTR lines. The only consistent differ-
ence between the clones was a reduction in the relative amounts
of the higher m/z structures in the CFTR cell lines, which
probably reflects the lower amount of mucin analyzed. Where
sufficient material was available, the sequences of glycans whose
compositions represent both core 2 and extended core 1 struc-
tures were defined by CAD ES-MS/MS. Representative data
are shown for the compositions at m/z 1,157, m/z 1,344, and m/z
1,432 (Figure 4) and confirmed the structural predictions shown
Leir, Parry, Palmai-Pallag, et al.: CFTR Expression and Mucin O-Glycosylation 457
TABLE 1. Summary of pseudomolecular ions observed in MALDI-TOF
of permethylated O-glycans from the epitope-tagged MUC1F/5ACTR
mucins and assignment of predicted structures. The following carbo-
hydrate residues are represented: N-acetylgalactosamine (filled squares);
N-acetylglucosamine (open squares); galactose (filled circles); N-acetyl-
neuraminic acid (open diamonds); and fucose (open triangles).
in Table 1. Further, in all cases where more than one structure
could contribute to a peak, (e.g., m/z 1,157, m/z 1,344, and m/z
1,432) the components were equivalent between MUC1F/
5ACTR mucins made in CFT1-LC3 and CFT1-LCFSN cells
(Figure 4).
Evaluation of the O-Glycosylation and Sulphation
of MUC1F/5ACTR by Metabolic Labeling
The relative levels of glycosylation and sulphation of MUC1F/
5ACTR glycoprotein purified from three CFT1-LC3 CFTR-
mutant cell lines (L15, L23, and L28) and three CFT1-LCFSN
CFTR-corrected cell lines (C03, C13, and C16) were evaluated.
The cell lines were grown to 40% confluence, washed in PBS,
and labeled with 14C amino acids and 3H glucosamine to measure
bulk O-glycosylation and with 35S sulfate and 3H glucosamine to
measure overall sulphation of MUC1F/5ACTR mucins. Immu-
noprecipitated material was separated on SDS-PAGE gels and
visualized by autoradiography and the gel areas containing
MUC1F/5ACTR seen in each cell line were excised. The amount
of 14C amino acids and 3H glucosamine or 3H glucosamine and
35S sulfate present onMUC1F/5ACTRwas determined by scintil-
lation counting of these excised gel slices. Ratios of 3H glucos-
amine to 14C amino acids (indicating levels of glycosylation) and
of 35S sulfate to 3H glucosamine (indicating levels of sulphation)
were determined in a minimum of three independent labeling
experiments (see Table 2).
Though the gross levels of glycosylation (3H/14C ratio) for the
MUC1F/5ACTR mucin were slightly lower in the CFT1-LC3
clones (L15, L23, and L28) (3.43–3.92) than in the wild-type
CFTR corrected CFT1-LCFSN clones C03 and C16 (3.65–9.14),
this difference was not statistically significant (P  0.333, t test).
MUC1F/5ACTR mucin expressed in the C13 clone showed a
consistently much higher level of glycosylation (3H/14C ratio of
9.14  1.08) than mucin extracted from the C03 and C16 clones;
however, this is thought to reflect clonal variation.
The level of sulphation of the MUC1F/5ACTR mucin in the
three CFT1-LC3 clones (L15, L23, L28) and the three CFT1-
LCFSN clones, C03, C13, and C16 showed no significant differ-
ences, with 35S/3H ratios between  0.17 and 0.36 (P  0.827,
t test). MUC1F/5ACTR mucin from individual CFTR-corrected
clones showed a greater variation in sulphation levels than mate-
rial derived from uncorrected clones; however, this is likely to
be due to clonal variation in sulphotransferase activity.
To further evaluate the gross sulphation of the MUC1F/
5ACTRmucin in terms of the protein backbone of the molecule,
rather than per unit sugar on the glycoprotein, the ratios of 35S
sulfate to 3H-amino acids were measured in a separate set of
experiments. The levels of sulphation of MUC1F/5ACTRmucin
in the three CFT1-LC3–derived clones and the three CFT1-
LSCFN–derived clones were similar (ratio 35S / 3H-aa 0.17–0.21,
P  0.618) (Table 3).
DISCUSSION
Elucidation of the cause of the failure to clear thickened mucous
secretions from the organ systems that are obstructed in CF
could make a significant contribution to the treatment of this
common genetic disease. Alterations in mucin glycosylation and
sulphation in CF airway, salivary, and intestinal secretions have
been reported in a number of studies using mucin purified from
patients with CF (16–18, 36–38). However, the interpretation of
these data is complicated by potential secondary modifications
of the mucins that occur after secretion, for example as a result of
infection and/or inflammatory responses in the epithelia. These
extracellular manifestations make it difficult to differentiate the
potential intracellular effects of mutant CFTR on mucin post-
translational processing. Studies ofmucin processing in epithelial
cell cultures derived from patients with CF should circumvent
these potential secondary extracellular modifications of the mu-
cins. Previous analyses of mucins derived from CF nasal epithe-
lial cell cultures (19) and xenograft models (13) suggested that
CF mucins exhibited higher levels of sulphation, and that this
defect could be corrected by expression of wild-type CFTR (21);
however, other data did not confirm this (22, 23). Several studies
showed that the sulphation or glycosylation of mucins was inde-
pendent of wild-type CFTR expression (22, 23).
The underlying cause of alterations in CF mucin glycoprotein
processing has received considerable attention. One hypothesis
was based on the observation that the trans-Golgi network was
unusually alkaline in CF cells due to reduced chloride conduc-
tance (2, 11, 12). Because glycoprotein-processing enzymes have
distinct pH optima, this defective acidification of theGolgi would
be predicted to have a significant impact on for example fucosyla-
tion, sulphation, and sialylation. However, other groups have
reported that the pH of the trans Golgi is not influenced by
expression of wild-type or mutant CFTR within cells (14, 39).
We investigated the processing of a single mucin type within
a matched set of cell lines, which differed only with respect
to CFTR expression (mutant or wild-type). Our aim was to
determine whether the production of thickened mucous secre-
tions by CF epithelial cells was a result of biochemical defects
occurring within the cell, or arising outside the cell, following
secretion into the airway/duct lumen. The latter would be consis-
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Figure 4. ES-MS/MS spectra from MUC1F/5ACTR
O-glycans. Tandem electrospray mass spectrometry of
permethylated O-glycans fromMUC1F/5ACTR purified
from CFT1-LC3 L28 and CFT1-LCFSN C13. The doubly-
charged ions corresponding to m/z 1,157, m/z 1,344,
and m/z 1,432 in Figure 3 were selected for collisional
activation.CADMS/MS spectra of [M2Na]2m/z590,
m/z 684, and m/z 728 from CFT1-LC3 (A, D, and G,
respectively) andCFT1-LCFSN (B, E, andH, respectively)
are shown. Diagnostic fragmentation ions correspond-
ing to each type of structure are shown (C, F, and I ).
The annotated ions not assigned in the schematics at
m/z 472, m/z 506, m/z 529, and m/z 733 correspond
to double cleavages. Symbols correspond to those de-
fined in Table 1.
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Figure 4. Continued.
tent with an altered milieu in CF airways causing the thickened
secretions (13).
We previously showed that CFTR expression did not influ-
ence glycosylation and sulphation ofMUC1mucin in colon carci-
noma cell lines (26). For the current studies we used the airway
epithelial cell line CFT1-LC3 derived from a F508 patient with
CF and its wild-type CFTR-corrected pair CFT1-LCFSN. Before
use we confirmed, using RT-PCR, that these cells lines main-
tainedCFTRmRNAexpression (Figure 2B and data not shown),
in contrast to several other putative matched pairs of CFTR
and CFTR corrected airway cell lines. In addition, we used
the chimeric mucin system that we have shown previously to be
valid for studying the O-glycosylation of mucins (29, 34). We
compared the O-glycosylation and sulphation of MUC1F/
5ACTR mucin (the TR of the major airway mucin MUC5AC
carried in an epitope-tagged MUC1 mucin) stably expressed in
TABLE 2. GLYCOSYLATION OF AMINO ACIDS AND SULPHATION OF GLYCANS
ON MUC1F/5ACTR IN CFTR MUTANT AND CFTR-CORRECTED CELL LINES
Clones MUC1F/5ACTR Expression CFTR Expression 3H/14C 35S/3H
C03 Low WT corrected 3.78  0.61 0.36  0.11
C13 High WT corrected 9.14  1.08 0.17  0.05
C16 High WT corrected 3.65  0.25 0.22  0.00
L15 Low F508 mutant 3.43  0.60 0.27  0.11
L23 High F508 mutant 3.92  0.46 0.27  0.02
L28 High F508 mutant 3.78  0.61 0.25  0.11
Definition of abbreviations: CFTR, cystic fibrosis transmembrane conductance regulator; WT, wild-type.
Results are shown as ratios of d-[6-3H] glucosamine hydrochloride (glucosamine) to [U-14C] protein hydrolysate (amino acids)
and 35S-sodium sulphate to d-[6-3H] glucosamine (35S/3H, sulphation) and  SEM. P value between WT corrected clones and
F508 mutant clones, t test: 3H/14C, P  0.333; 35S/3H, P 0.827. Data are derived from three separate experiments with triplicate
cultures of each clone.
the CFT1-LC3 and CFT1-LCSFN cells, by using a quantitative
metabolic labeling assay and qualitativeMS analysis. This experi-
mental system has enabled us to ask directly, if the presence of
mutant or wild-type CFTR in an airway epithelial cell directly
affects the biochemical properties of a singlemucin glycoprotein.
CFTR Expression Causes No Qualitative Difference
in the O-glycans of MUC1F/5ACTR
Preliminary data from Western blot evaluation of the MUC1F/
5ACTR mucins expressed in the CFT1-LC3 and CFT1-LCFSN
lines suggested that there were no gross differences in their
sialylation or sulphation because all glycoforms showed similar
migration irrespective of their CFTR status. Sialylation and sul-
phation are known to affect the mobility of molecules in SDS-
PAGE (40).
We previously used antibodies directed against carbohydrate
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TABLE 3. TOTAL MUC1F/5ACTR SULPHATION IN CFTR
MUTANT AND CFTR-CORRECTED CELL LINES
Clones MUC1F/5ACTR Expression CFTR Expression 35S/3H-aa
C03 Low WT corrected 0.20  0.04
C13 High WT corrected 0.18  0.03
C16 High WT corrected 0.17  0.05
L15 Low F508 mutant 0.18  0.08
L23 High F508 mutant 0.21  0.11
L28 High F508 mutant 0.18  0.06
For definition of abbreviations see Table 2.
Results are shown as ratios of 35S-sodium sulphate to [3H] amino acids  SEM.
P value between WT corrected clones and F508 mutant clones, t test: P 0.618.
Data were collected from two separate experiments with triplicates of each clone.
structures to show that CFTR expression does not influence
O-glycosylation of the epitope-taggedMUC1F in colon carcinoma
cells (26). The current data confirm this and extend the studies
by using MALDI-TOF and ES mass spectrometry to examine
the carbohydrate structures in detail. Evaluation of the MUC1F/
5ACTR chimeric mucin by MALDI-TOF mass spectrometry to
determine the O-glycan compositions carried by this molecule
indicated that no novelO-glycan structureswere present in either
the CFT1-LC3 or CFT1-LCFSN–derived cell lines. All 12 O-gly-
cans detected in CFTR mutant cells were also seen in cells that
expressed wild-type CFTR. Though some minor differences were
seen in the abundance of a few of the peaks, these are likely to
reflect individual clonal variation or sample abundance differ-
ences rather than a consistent difference between the CFTR
and CFTR lines. If there was a relative increase in mucin
fucosylation associated with CF, then either additional fucosy-
lated derivates would be observed in the CFT1-LC3 clones, and/
or the relative abundance (in comparison to similar m/z peaks
that are not fucosylated) of the m/z 708, m/z 1,157, and m/z
1,606 would be increased. This does not appear to be the case.
Similarly, the decrease in sialylation that has been reported for
mucins synthesized in CF cells would predict a relative decrease
in the abundance (in comparison to similar m/z peaks that are
nonsialylated) of peaks at m/z 895, m/z 1,256, m/z 1,344, m/z
1,518, m/z 1,705, and m/z 1,793. Again, this is not observed and
variations in abundance are seen in core 1 and sialylated or
fucosylated core 2 structures rather than the variable peaks all
carrying same modification. Additional structural information
was obtained by CADES tandemmass spectrometry of selected
pseudomolecular ions. In each case where peaks could contain
a mixture of glycans, these were of similar abundance in the
CFT1-LC3 and CFT1-LCFSN clones. It is of interest that the
glycans seen on the MUC1F-derived mucins in the 16HBE140
cell line, an SV40-transformed airway cell line, show significant
differences from those detected here in the CFT1-LC3 and
CFT1-LCSFN airway lines (41, 42). This further illustrates the
importance of carrying out this type of study in appropriately
matched cell strains. The failure to detect consistent differences
in the glycosylation, including the fucosylation and sialylation
of MUC1F/5ACTR expressed in CFTR mutant and wild-type
corrected airway epithelial cells, suggests that mucin abnormali-
ties observed in CF secretions are not caused by intracellular
events that alter the glycoprotein processing machinery.
CFTR Expression Causes No Quantitative Differences in the
O-Glycosylation or Sulphation of MUC1F/5ACTR
Because MALDI mass spectroscopy is not a definitively quanti-
tative technique, we next examined gross glycosylation and sul-
phation of MUC1F/5ACTR in F508 CFTR (CFT1-LC3) and
WT CFTR CFT1-LCFSN cells by metabolic labeling. Individual
clones derived from the same parental cell line may express
different phenotypic characteristics in culture. Further, the clonal
variation in glycoprotein processing enzymes has been illustrated
previously (23); hence, we performed metabolic labeling experi-
ments in three clones each of CFT1-LC3 and CFT1-LCFSN ex-
pressing MUC1F/5ACTR. First, ratios of [3H]-glucosamine to
[14C]-amino acids (3H/14C) were measured to quantify the overall
O-glycosylation. The gross levels of O-glycosylation of MUC1F/
5ACTR chimeric mucin did not differ significantly in the CFT1-
LC3 and CFT1-LCFSN cell lines, except that a 2-fold increase
in the 3H/14C ratio was consistently observed in the CFT1-LCFSN
clone C13. This indicates a high level of glycosylation that is
likely to be an example of clonal variation in the glycosylation
machinery, as it was not observed in the C03 or C16 clones.
Next, we compared the ratios of [35S]-Na2SO4 to [3H]-glucosamine
(35S/3H) as a measure of overall sulphation of glycans. Finally,
the overall sulphation of the MUC1F/5ACTR glycoprotein was
evaluated by comparing the ratios of [35S]-Na2SO4 to [3H]-amino
acids (35S/3H-aa) in the same culture. Neither method revealed
a significant difference in the gross levels of sulphation of the
MUC1F/5ACTRmucin expressed in mutant or wild-type CFTR
airway cells.
In conclusion, using an airway cell culture system, with two
cell lines that differ only with respect to mutant or wild-type
CFTR expression, we found no qualitative (by mass spectrome-
try) or quantitative (by metabolic labeling) evidence for a direct
link betweenO-glycosylation (including sialylation and fucosyla-
tion) or sulphation of a single mucin type and normal CFTR
expression. Thus, our data, which are in agreement with another
recent study (43), fail to support the hypothesis that the thick-
ened mucous secretions characteristic of the CF respiratory sys-
tem arise due to primary defects in mucin biochemistry that
result from the absence of wild-type CFTR in the cell. Rather,
these data are consistent with the mucin abnormalities arising
outside the airway epithelial cell, most probably as a secondary
effect of the altered airway surface liquid in CF.
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